As GLP-1 use rises in Maine, insurance is less likely to cover the medications

Tammie Rogers, a 52-year-old Dayton resident, began using Zepbound, a GLP-1 medication, last year after her pulmonologist recommended it to address her sleep apnea and obesity. The drug helped her lose 40 pounds, alleviating joint pain and improving her sleep, though she now faces a January 2026 insurance coverage cutoff for weight loss treatment. Insurers like Anthem and Harvard Pilgrim Health Care have excluded GLP-1 coverage for obesity from most plans in 2026, a trend followed by many large employers. Eric Jermyn, an insurance broker in Bangor, estimates fewer than 10% of employers cover GLP-1s for weight loss, though coverage remains for conditions like diabetes. The medications’ rapid rise in demand has driven costs up, prompting insurers to restrict access. GLP-1 drugs have transformed patients’ lives, offering new control over eating habits and improving long-term health prospects, according to Rogers and other Maine residents. However, their widespread use coincides with emerging research on long-term efficacy and side effects, leaving questions about their cost-effectiveness for employers. Maine’s obesity rate has surged nearly 300% since 1990, with about one-third of residents classified as obese, contributing to higher healthcare costs. The Maine Medical Association argues GLP-1s could ultimately reduce healthcare expenses by treating obesity as a disease, but insurers remain skeptical amid rising prescription demand. Rogers and advocates criticize the trend as short-sighted, emphasizing that obesity is a medical condition requiring treatment. Without insurance coverage, patients like Rogers may struggle to afford the medications, despite their proven benefits in weight loss and related health improvements.